<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="74058">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02151643</url>
  </required_header>
  <id_info>
    <org_study_id>PT20-201</org_study_id>
    <nct_id>NCT02151643</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Efficacy and Safety of PT20 in Subjects With Hyperphosphataemia and Dialysis Dependent Chronic Kidney Disease</brief_title>
  <official_title>Study to Evaluate the Efficacy and Safety of PT20 in Subjects With Hyperphosphataemia and Dialysis Dependent Chronic Kidney Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Phosphate Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Phosphate Therapeutics</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to see whether PT-20 can help people with a high level of
      phosphate in their blood (called Hyperphosphatemia) that are being treated with dialysis for
      kidney disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Elevated serum phosphate is a ubiquitous complication of reduced kidney function and
      evidence suggests that this metabolic disturbance is associated with cardiovascular
      morbidity and mortality in subjects receiving haemodialysis Efforts to achieve normal serum
      phosphate with dietary restrictions, thrice weekly dialysis and phosphate binders have
      failed to substantially improve the achieved serum phosphate levels. Data from a large
      international practice pattern study suggest that approximately 50% of all dialysis subjects
      have serum phosphate above the recommended target value of 5.5 mg/dL The standard of care
      for phosphate control remains the prescription of phosphate binders with meals. These drugs
      act in the small intestine to bind phosphate and prevent its absorption into the
      bloodstream. The 2 general categories of phosphate binders currently commercially available
      include calcium containing phosphate binders (calcium carbonate and calcium acetate) and the
      non calcium containing phosphate binders (sevelamer carbonate and lanthanum carbonate While
      these 2 classes of phosphate binders have similar efficacy, they differ substantially in
      their associated side effects.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">January 2015</completion_date>
  <primary_completion_date type="Anticipated">January 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>To assess the effect of oral PT20 over placebo on serum phosphate</measure>
    <time_frame>Day 28 of Dosing</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>• To assess the safety and tolerability of PT20 utilising adverse events (AEs), discontinuations from study medication and laboratory values.</measure>
    <time_frame>Day 1 to Day 28 of dosing</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>• To assess gastrointestinal effects using the gastrointestinal symptom rating scale (GSRS).</measure>
    <time_frame>Day 1 to Day 28 Dosing</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Hyperphosphataemia</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PT20 400 mg t.i.d</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PT20 800 mg t.i.d</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PT20 1600 mg t.i.d</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PT20 3200 mg t.i.d</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 5</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matched Placebo t.i.d</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PT20</intervention_name>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_label>Group 4</arm_group_label>
    <other_name>Iron (III) oxide adipate</other_name>
    <other_name>ferric oxide adipate</other_name>
    <other_name>iron (III) oxide hydroxide adipate</other_name>
    <other_name>M10L78</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men or women aged 18 90 years

          -  Subject must have a stable dialysis prescription for at least 28 days prior to  start
             of Screening.

          -  Subject must have the most recent serum phosphate measurement, taken during the 28
             days prior to the start of Screening, of ≥ 4.0 mg/dL and ≤ 8 mg/dL.

        Exclusion Criteria:

          -  Subject's most recent historical pre-dialysis serum bicarbonate value within 14 days
             prior to the start of Screening (Visit 1) is &lt; 18 mg/dL.

          -  Subject has, in the opinion of the investigator, severe chronic lung disease and/or
             carbon dioxide retention.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Geoff Block, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Denver Nephrologist</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Julian Howell, MBBS</last_name>
    <role>Study Director</role>
    <affiliation>Phosphate Therapeutics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Southwest Clinical Research Institute, LLC</name>
      <address>
        <city>Tempe</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Advanced Kidney Medical Group, Inc</name>
      <address>
        <city>Bakersfield</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tabetha Edwards</last_name>
      <email>tedwards@nicresearch.com</email>
    </contact>
    <investigator>
      <last_name>Hashim Kazmi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kidney Wellness Center</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sean Sana</last_name>
      <email>ssana@nicresearch.com</email>
    </contact>
    <investigator>
      <last_name>George Hon</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ontario Dialysis Center</name>
      <address>
        <city>Ontario</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kidney Center, Inc.</name>
      <address>
        <city>Simi Valley</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shekhar Dhokai</last_name>
      <email>shekhar.clinical@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Kant Tucker</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>American Institute of Research</name>
      <address>
        <city>Whittier</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Denver Nephrologist</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80230</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>South Florida Research Institute</name>
      <address>
        <city>Lauderdale Lakes</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>NorthShore University HealthSystem</name>
      <address>
        <city>Evanston</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Northwest Louisiana Nephrology</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deanna Ferrell</last_name>
      <email>deannaf@nwln.com</email>
    </contact>
    <investigator>
      <last_name>Marwan Kaskas</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A. Kaldun Nossuli, MD -- Research</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nephrology Associates, P.C.</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shinieka Wilson</last_name>
      <email>swilson@tnkidney.com</email>
    </contact>
    <investigator>
      <last_name>Douglas Linfert</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Arlington Nephrology</name>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Millennium Clinical Research, Inc</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Southwest Houston Research, Ltd.</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>U.S. Renal Care</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maricela Garcia</last_name>
      <email>margarcia@clinicalresearchconnections.com</email>
    </contact>
    <investigator>
      <last_name>Reza Mizani</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kidney &amp; Hypertension Specialists</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin - Madison</name>
      <address>
        <city>Fitchburg</city>
        <state>Wisconsin</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 28, 2014</lastchanged_date>
  <firstreceived_date>May 28, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dialysis Dependent Chronic Kidney Disease</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Hyperphosphatemia</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
